NO980030L - Monoklonale antistoffer som binder CD40-L - Google Patents

Monoklonale antistoffer som binder CD40-L

Info

Publication number
NO980030L
NO980030L NO980030A NO980030A NO980030L NO 980030 L NO980030 L NO 980030L NO 980030 A NO980030 A NO 980030A NO 980030 A NO980030 A NO 980030A NO 980030 L NO980030 L NO 980030L
Authority
NO
Norway
Prior art keywords
bind
monoclonal antibodies
immunogen
disclosed
isolated antibody
Prior art date
Application number
NO980030A
Other languages
English (en)
Other versions
NO320073B1 (no
NO980030D0 (no
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO980030(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO980030D0 publication Critical patent/NO980030D0/no
Publication of NO980030L publication Critical patent/NO980030L/no
Publication of NO320073B1 publication Critical patent/NO320073B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19980030A 1991-10-25 1998-01-05 Antistoffer som binder CD40-L NO320073B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
NO980030D0 NO980030D0 (no) 1998-01-05
NO980030L true NO980030L (no) 1998-01-05
NO320073B1 NO320073B1 (no) 2005-10-17

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.

Country Status (13)

Country Link
EP (2) EP0897983B1 (no)
JP (2) JP3308534B2 (no)
KR (1) KR100283541B1 (no)
AT (2) ATE274055T1 (no)
AU (1) AU661360B2 (no)
CA (2) CA2312667C (no)
DE (2) DE69233051T2 (no)
DK (3) DK0667901T4 (no)
ES (2) ES2198025T3 (no)
FI (2) FI116850B (no)
HK (1) HK1019343A1 (no)
NO (2) NO317625B1 (no)
WO (1) WO1993008207A1 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE256180T1 (de) * 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
EP0612529B1 (en) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
DE69418349T2 (de) * 1993-09-02 1999-09-09 Dartmouth College Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
AU696235B2 (en) 1993-09-02 1998-09-03 Bristol-Myers Squibb Company Anti-GP39 antibodies and uses therefor
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
US5674492A (en) * 1993-12-23 1997-10-07 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
EP0763057B1 (en) 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for proliferating and differentiating b cells, and uses thereof
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
CA2222914C (en) * 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5971158A (en) * 1996-06-14 1999-10-26 University Of Washington Absorption-enhanced differential extraction device
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP2371962A3 (en) * 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
ES2279649T3 (es) * 1998-10-23 2007-08-16 Amgen Inc. Compuestos trombopoyeticos.
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2003508016A (ja) * 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
PT1434871T (pt) 2001-09-20 2017-04-05 Immunex Corp Seleção de células que expressam polipéptidos heteroméricos
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
GEP20105059B (en) 2004-07-26 2010-08-10 Biogen Idec Inc Anti-cd154 antibodies
JP5269412B2 (ja) 2004-10-07 2013-08-21 アルゴス セラピューティクス，インコーポレイティド 成熟樹状細胞組成物およびその培養方法
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EA012162B1 (ru) 2004-10-22 2009-08-28 Эмджен Инк. Способ рефолдинга рекомбинантных антител
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
CA2704457A1 (en) 2007-10-30 2009-05-07 Walter Bottje Compositions and methods of enhancing immune responses to flagellated bacterium
PL3097926T3 (pl) 2007-11-01 2020-04-30 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
RU2502800C2 (ru) 2008-01-15 2013-12-27 Эббви Инк. Усовершенствованные векторы экспрессии млекопитающих и их применение
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ702839A (en) 2010-06-09 2016-04-29 Univ Arkansas Vaccine and methods to reduce campylobacter infection
SG11201506398SA (en) 2013-02-14 2015-09-29 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
JP6530742B2 (ja) 2013-03-15 2019-06-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 腸内病原体の免疫応答を強化する組成物及び方法
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
ES2944982T3 (es) 2015-08-05 2023-06-27 Janssen Biotech Inc Anticuerpos anti-CD154 y métodos para utilizarlos
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
BR112018073316A2 (pt) 2016-05-11 2019-06-04 Amgen Inc seleção direta de células que expressam altos níveis de proteínas heteroméricas usando vetores de complementação intragênica da glutamina sintetase
US11267856B2 (en) * 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
CA2121798A1 (en) 1993-04-29
FI941837A0 (fi) 1994-04-20
FI981765A0 (fi) 1998-08-17
DK0822199T3 (da) 2004-12-27
JP3308534B2 (ja) 2002-07-29
FI981765A (fi) 1998-08-17
CA2121798C (en) 2007-07-24
EP0667901A4 (en) 1995-06-22
NO320073B1 (no) 2005-10-17
NO980030D0 (no) 1998-01-05
AU3122693A (en) 1993-05-21
DE69233051T2 (de) 2004-03-11
DK0667901T3 (da) 2004-12-27
NO941422D0 (no) 1994-04-19
HK1019343A1 (en) 2000-02-03
DE69233051D1 (de) 2003-06-12
ATE274055T1 (de) 2004-09-15
FI116828B (fi) 2006-03-15
FI116850B (fi) 2006-03-15
EP0897983A2 (en) 1999-02-24
EP0897983B1 (en) 2003-05-07
EP0667901B2 (en) 2008-10-15
EP0667901B1 (en) 2004-08-18
DK0667901T4 (da) 2008-11-10
EP0897983A3 (en) 1999-03-17
NO941422L (no) 1994-06-27
ATE239790T1 (de) 2003-05-15
JPH07504083A (ja) 1995-05-11
NO317625B1 (no) 2004-11-29
FI941837A (fi) 1994-05-30
CA2312667C (en) 2002-11-19
AU661360B2 (en) 1995-07-20
JPH10150994A (ja) 1998-06-09
JP2877788B2 (ja) 1999-03-31
ES2198025T3 (es) 2004-01-16
ES2227513T5 (es) 2009-04-01
DK0897983T3 (da) 2003-08-11
KR100283541B1 (ko) 2001-03-02
WO1993008207A1 (en) 1993-04-29
DE69233402T3 (de) 2009-06-25
DE69233402T2 (de) 2005-09-15
CA2312667A1 (en) 1993-04-29
DE69233402D1 (de) 2004-09-23
ES2227513T3 (es) 2005-04-01
EP0667901A1 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
NO980030D0 (no) Monoklonale antistoffer som binder CD40-L
NL300387I1 (nl) Antilichaam tegen menselijke interleukine-6-receptor
DE68914244T2 (de) Monoklonaler Antikörper.
CY2006001I2 (el) Ανθρωποποιημενο heregulin αντισωμα
DK666389D0 (da) Monoklonalt antistof
GB2144147B (en) Monoclonal antibody having only one light chain which will bind a specific antigen
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
DK49291A (da) Gramnegativ-bakterieendotoxinblokerende, monoklonale antistoffer
DK474189A (da) Monoklonalt antistof
NO890116L (no) Monoklonale antistoffer.
DE69023717D1 (de) Monoklonaler Antikörper.
DE68912772T2 (de) Monoklonaler antikörper gegen entero-viren.
DK413389A (da) Monoklonale antistoffer
DE68916088T2 (de) Anti-CPBII-monoklonaler Antikörper.
DE69118827D1 (de) Antikörper gegen Hamsterimmunglobulinen
FI960566A (fi) Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
DK220688D0 (da) Monoklonalt antistof

Legal Events

Date Code Title Description
MK1K Patent expired